-transparent.png){kind=logo}
Docetaxel (Taxotere) is a new cytotoxic compound with a broad spectrum of activity in preclinical studies. This paper reports a phase II trial in patients with previously-treated small cell carcinoma of the lung. 34 patients received 100 mg/m2 of docetaxel in an intravenous infusion given over 1 h every 21 days. Seven partial responses were reported (25% of 28 evaluable patients). Duration of response was 3.5-12.6 months. Toxicities were predominantly neutropenia, alopecia and asthenia. Docetaxel is a new compound with activity in previously-treated patients with small cell lung cancer, and is suitable for evaluation in combination with other cytotoxic drugs active in this disease.
J F Smyth, and
I E Smith, and
C Sessa, and
P Schoffski, and
J Wanders, and
H Franklin, and
S B Kaye
August 1994,
British journal of cancer,
J F Smyth, and
I E Smith, and
C Sessa, and
P Schoffski, and
J Wanders, and
H Franklin, and
S B Kaye
January 1994,
European journal of cancer (Oxford, England : 1990),
J F Smyth, and
I E Smith, and
C Sessa, and
P Schoffski, and
J Wanders, and
H Franklin, and
S B Kaye
August 1994,
British journal of cancer,
J F Smyth, and
I E Smith, and
C Sessa, and
P Schoffski, and
J Wanders, and
H Franklin, and
S B Kaye
January 1994,
European journal of cancer (Oxford, England : 1990),
J F Smyth, and
I E Smith, and
C Sessa, and
P Schoffski, and
J Wanders, and
H Franklin, and
S B Kaye
January 1998,
The oncologist,
J F Smyth, and
I E Smith, and
C Sessa, and
P Schoffski, and
J Wanders, and
H Franklin, and
S B Kaye
August 1994,
British journal of cancer,
J F Smyth, and
I E Smith, and
C Sessa, and
P Schoffski, and
J Wanders, and
H Franklin, and
S B Kaye
August 1997,
Seminars in oncology,
J F Smyth, and
I E Smith, and
C Sessa, and
P Schoffski, and
J Wanders, and
H Franklin, and
S B Kaye
June 1999,
Seminars in oncology,
J F Smyth, and
I E Smith, and
C Sessa, and
P Schoffski, and
J Wanders, and
H Franklin, and
S B Kaye
April 2002,
Current medicinal chemistry,
J F Smyth, and
I E Smith, and
C Sessa, and
P Schoffski, and
J Wanders, and
H Franklin, and
S B Kaye
February 1996,
British journal of cancer,
